No Data
junshi bio (01877) published Phase 2 study data of anti-PD-1 monoclonal antibody for nasopharyngeal carcinoma, with a patient objective response rate of 61.9%.
On November 6, junshi bio (01877) announced that the latest data from the Phase 2 study of the clinical research on the first-line treatment of cisplatin-resistant R/M NPC with Teripulimab combined with gemcitabine for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients intolerant to cisplatin was published in the international journal Cell Reports Medicine.
Increased revenue but no increase in profit, junshi bio (01877) faces numerous hidden worries behind its growth.
In the third quarter, revenue increased without profit growth, junshi bio cut research and development expenses to reduce losses, but shareholders faced market questioning as they reduced their holdings when a new drug was approved~
HK stocks unusual movement: junshi bio (01877) is currently down by over 4%, with a net loss of 0.927 billion yuan in the first three quarters. Shareholders have recently collectively reduced their shareholding by over 1%.
junshi bio (01877) is now down more than 4%, as of the time of publication, down 4.2%, at 13.24 Hong Kong dollars, with a turnover of 11.964 million Hong Kong dollars.
Shareholders in Shanghai Junshi Biosciences (HKG:1877) Have Lost 65%, as Stock Drops 4.2% This Past Week
junshi bio announced that shanghai Tan Ying and its concerted action persons collectively reduced their shareholding by more than 1% of the company's equity.
junshi bio (01877) announced that from August 24, 2023 to October 8, 2024, LVC Renaissance Fund, LVC Fund I, and LVC Fund II reduced their H shares due to fund duration and liquidity arrangements, totaling approximately 8.241 million H shares. On September 25, 2024, the company disclosed the Announcement of Shanghai junshi bio biomedical technology limited regarding shareholders holding more than 5% of the shares reducing the shareholding plan (announcement number: temporary)
Junshi Biotech Report for the Third Quarter of 2024
No Data
No Data